Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Christofori, Gerhard" or (type any "bookEditor issueEditor" and editor="Christofori, Gerh...

Add to list
- Journal Article
- A1
- open access
Guidelines and definitions for research on epithelial–mesenchymal transition

Jing Yang, Parker Antin, Geert Berx (UGent) , Cédric Blanpain, Thomas Brabletz, Marianne Bronner, Kyra Campbell, Amparo Cano, Jordi Casanova, Gerhard Christofori, et al.

(2020) NATURE REVIEWS MOLECULAR CELL BIOLOGY. 21(6). p.341-352
Add to list
- Journal Article
- A1
- open access
Tenascin-C downregulates Wnt inhibitor Dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model

Falk Saupe, Anja Schwenzer, Yundan Jia, Isabelle Gasser, Caroline Spenlé, Benoit Langlois, Martial Kammerer, Olivier Lefebvre, Ruslan Hlushchuk, Tristan Rupp, et al.

(2013) CELL REPORTS. 5(2). p.482-492
Add to list
EMT as the ultimate survival mechanism of cancer cells

Neha Tiwari, Alexander Gheldof (UGent) , Marianthi Tatari and Gerhard Christofori

(2012) SEMINARS IN CANCER BIOLOGY. 22(3). p.194-207
Add to list
Concepts of metastasis in flux: the stromal progression model

Jonathan P Sleeman, Gerhard Christofori, Riccardo Fodde, John G Collard, Geert Berx (UGent) , Charles Decraene and Curzio Rüegg

(2012) SEMINARS IN CANCER BIOLOGY. 22(3). p.174-186
Add to list
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease

Sara Van de Veire, Ingeborg Stalmans, Femke Heindryckx (UGent) , Hajimu Oura, Annemilai Tijeras-Raballand, Thomas Schmidt, Sonja Loges, Imke Albrecht, Bart Jonckx, Stefan Vinckier, et al.

(2010) CELL. 141(1). p.178-190

Academic Bibliography

Guidelines and definitions for research on epithelial–mesenchymal transition

Tenascin-C downregulates Wnt inhibitor Dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model

EMT as the ultimate survival mechanism of cancer cells

Concepts of metastasis in flux: the stromal progression model

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease

Contents

Support

Contact